RESEARCHER: Dr. Jesús Merayo Lloves  ACTIVO    A multicentre, randomized, double masked, 4-parallel, controlled, 6-month phase II study to assess the safety and efficacy of a cyclosporine PAD ophthalmic dispersion (0.06% and 0.03% CsA). Administered once daily in combination with lubricant therapy and safety

  RESEARCHER: Dr. Jesús Merayo Lloves  RECLUTANDO    "Double-blind, placebo-controlled phase I / II study to assess the efficiency and safety of AVX012 ophthalmic solution in subjects with mild to moderate dry eye" INDICATION: Pacientes con ojo seco leve o moderado TREATMENT: AVX-012 PROMOTOR: Avizorex Pharma

  RESEARCHER: Dr. Álvaro Fernández-Vega Sanz  ACTIVO    Treatment of age-related macular degeneration of the neovascular type (DMAEh) over 2 years with a treatment and extension model (T + E) of 2 mg aflibercept injected into the eye. INDICATION: Patients with Macular Degeneration Associated with the

  RESEARCHER: Prof. Luis Fernández-Vega Sanz  RECLUTANDO    A dose-Ranging, Muti-Centre, Randmised, Double-Mased, Sham-Controlled, Parallel-Group Study of the Efficacy and safety of Opt-302 in Combination wiht Ranibizumab Compared with Ranibizumab Alone, in Patients with Neovascular Age-Related Macular Degeneration ( Wet AMD) INDICATION: Pacientes con degeneración macular

  RESEARCHER: Dr. Álvaro Fernández-Vega Sanz  ACTIVO    Phase IV, randomized, double-blind, simulated control study for the efficacy, safety, and tolerability of Aflibercept intravitreal monotherapy compared to Aflibercept and Concomitant Photodynamic Therapy in patients with Polypoidal Choroidal Vasculopathy. (ATLANTIC) INDICATION: Patients with polypoid choroidal vasculopathy TREATMENT: Aflibercept PROMOTOR: AIBILI

  RESEARCHER: Dr. Álvaro Fernández-Vega Sanz  RECLUTANDO   

  RESEARCHER: Dr. Jesús Merayo Lloves  RECLUTANDO    Double masked SYL1001 study in patients with moderate or severe dry eye disease   INDICATION: Patients with moderate to severe dry eye TREATMENT: SYL1001 PROMOTOR: SYLENTIS